initial public offerings (IPOs) trading on American exchanges

Thursday, August 8, 2013

Intrexon (XON) began trading on the NYSE on 8 Aug 2013

Synthetic biology company Intrexon celebrate their IPO at the New York Stock Exchange on August 8, 2013 in New York City.


Intrexon Corporation is engaged in the business of synthetic biology. Using the Company’s suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. The Company’s LEAP technology facilitates the automated identification of an individual cell with the highest levels of expression, quality and potency from a population of over 100,000 cells.


20374 Seneca Meadows Parkway


Key stats and ratios

Q3 (Sep '13)2012
Net profit margin244.43%-586.00%
Operating margin-196.27%-539.73%
EBITD margin--482.39%
Return on average assets15.87%-61.24%
Return on average equity6758.35%-

No comments:

Post a Comment